Group 1 - The core point of the article is that Innovent Biologics has entered into a strategic partnership with Eli Lilly to advance global research and development of innovative drugs in oncology and immunology, with potential financial benefits amounting to $88.5 billion [1][4]. - Innovent will receive an upfront payment of $350 million and could earn up to $8.5 billion in milestone payments, along with a share of net sales outside Greater China [1][4]. - The Hong Kong Stock Connect Innovative Drug ETF (520880) is fully invested in innovative drug R&D companies and has shown strong performance, leading its peers since 2025 [1][4]. Group 2 - The ETF's index is characterized by high purity, elasticity, and sharpness, demonstrating strong offensive capabilities in the innovative drug rebound market [1][4]. - The top ten constituent stocks of the ETF account for over 73% of its weight, indicating a concentrated representation of the core strength in innovative drug development [1][4]. - The ETF has recorded varying returns over the past five years, with a notable increase of 66.32% in one of the periods analyzed [1][4].

Core Viewpoint - The collaboration between Innovent Biologics and Eli Lilly marks the seventh partnership since 2015, focusing on the global development of innovative drugs in oncology and immunology, showcasing Innovent's strong R&D capabilities recognized by multinational corporations [1] Event - On February 8, Innovent Biologics announced a strategic partnership with Eli Lilly to advance the global development of innovative drugs in oncology and immunology, with Innovent leading the projects from drug discovery to clinical concept validation in China [1] Financial Details - The collaboration includes an upfront payment of $350 million and a total package worth $8.85 billion, with Innovent retaining all rights in Greater China while Eli Lilly obtains exclusive global development and commercialization rights outside this region [1] - Innovent is eligible for up to approximately $8.5 billion in milestone payments related to R&D, regulatory, and commercialization, along with a tiered sales share from net sales outside Greater China [1] R&D Capacity - The partnership indicates high recognition of Innovent's early-stage R&D and concept validation capabilities in oncology and immunology by Eli Lilly, which has a strong portfolio in these areas [2] - Innovent has 17 commercialized drugs, with one product under NMPA review, four new drug molecules in Phase III or critical clinical studies, and 15 additional new drug candidates in clinical research [2] Profit Forecast and Investment Recommendation - Innovent's extensive layout in oncology is expected to enhance revenue and reduce marginal costs, while the company also has competitive products in metabolic, autoimmune, and ophthalmology fields [2] - A global strategic partnership with Takeda, valued at $11.4 billion, is anticipated to accelerate the introduction of next-generation IO and ADC therapies to the global market, marking a significant step in Innovent's internationalization [2] - Revenue projections for Innovent from 2025 to 2027 are estimated at 11.968 billion yuan, 22.804 billion yuan, and 26.572 billion yuan, with net profits of 0.886 billion yuan, 6.679 billion yuan, and 8.004 billion yuan respectively [2] - The company’s reasonable market value is estimated at 232.7 billion HKD, with a target price set at 136.12 HKD, maintaining a "buy" rating [2]

Investment Rating - The report assigns a "Buy" rating to the company, believing its current stock price is undervalued due to a high implied weighted average cost of capital of 12% [1] Core Insights - The report highlights that the company, Innovent Biologics, is expected to maintain its leading position in the Chinese biotechnology sector, driven by a strong pipeline of novel molecules targeting next-generation immuno-oncology [1] - Encouraging preliminary data has been obtained for IBI363, a PD-1/IL-2α bispecific antibody, which exhibits differentiated drug characteristics in immunotherapy and cold tumors [1] - The company's robust commercialization capabilities and deep collaboration with global partners, particularly Eli Lilly, are also emphasized as key strengths [1] Summary by Relevant Sections - **Investment Rating**: "Buy" rating with a target price of HKD 102.85 based on risk-adjusted discounted cash flow [1] - **Market Position**: Innovent Biologics is positioned as a leader in the Chinese biotech field, supported by a strong pipeline and strategic partnerships [1] - **Product Development**: IBI363 shows promising initial results, indicating potential for differentiation in the competitive landscape of immunotherapy [1] - **Commercialization Strength**: The company’s strong commercial capabilities and partnerships enhance its market prospects [1]

Core Viewpoint - Morgan Stanley reports that Innovent Biologics (01801) has entered into a strategic partnership with Eli Lilly (LLY.US) to jointly develop novel biologics focused on oncology and immunology globally [1] Group 1: Company Overview - Innovent Biologics is reaffirmed as a top pick among Chinese biotech companies covered by Morgan Stanley, with an "Overweight" rating and a target price of HKD 111 [1] - The collaboration is seen as a positive surprise and marks a significant milestone in Innovent's journey towards becoming a global biopharmaceutical company, highlighting the strength of its R&D platform [1] Group 2: Management and Strategy - During a conference call, Innovent's management reiterated its long-term vision, primarily supported by a dual-engine growth strategy in the areas of generic biologics and oncology drugs [1] - Morgan Stanley continues to be impressed by Innovent's execution capabilities in its commercial and R&D product lines, as well as its strong business development abilities [1]

Group 1 - The Hong Kong stock market closed with the Hang Seng Index rising by 0.58% and the Tech Index increasing by 0.62% [1] - Le Xin Outdoor (02720.HK) saw a first-day listing surge of over 100% [1] - CSPC Pharmaceutical Group (01093.HK) experienced a rise of over 5.5% [1] - Innovent Biologics (01801.HK) and Pop Mart (09992.HK) both increased by nearly 5% [1] - Oriental Selection (01797.HK) faced a decline of nearly 10% [1]

Group 1 - The Hong Kong stock market is experiencing a rally, with both the Hang Seng Index and the Hang Seng Tech Index rising over 1% [1] - The AI application and innovative pharmaceutical sectors are leading the gains in the market [1] - Companies such as Yu Wen Group and Zhi Pu have seen their stock prices increase by over 6%, while Kangfang Biotech and Innovent Biologics have risen by over 3% [1]

Core Viewpoint - The Hong Kong stock market's innovative pharmaceutical sector has seen significant gains, with companies like CSPC Pharmaceutical, WuXi Biologics, and Innovent Biologics rising over 5%, positively impacting various ETFs tracking innovative pharmaceuticals [1][4]. Group 1: Market Performance - CSPC Pharmaceutical, WuXi Biologics, and Innovent Biologics have all experienced stock price increases exceeding 5% [1]. - Multiple ETFs, including the Hong Kong Innovative Pharmaceutical ETFs managed by various firms, have also shown positive performance, with daily increases ranging from 2.50% to 3.27% [2]. Group 2: ETF Details - The Hong Kong Innovative Pharmaceutical ETF managed by Jiashi tracks the CSI Hong Kong Innovative Pharmaceutical Index, which includes leading companies like BeiGene, Innovent Biologics, and WuXi Biologics [4]. - The only ETF tracking the Hang Seng Hong Kong Innovative Pharmaceutical Index is the Hong Kong Innovative Pharmaceutical ETF managed by E Fund, focusing on core enterprises in the innovative drug industry [4]. Group 3: Strategic Collaborations - Innovent Biologics has entered a strategic partnership with Eli Lilly to advance global R&D in oncology and immunology, with a total payment of $88.5 billion, including an upfront payment of $3.5 billion [5]. - This collaboration is viewed positively by analysts, marking a significant milestone for Innovent Biologics and highlighting its R&D capabilities [5]. Group 4: Industry Trends - The number of new drug license-out transactions in China is projected to reach 158 by 2025, with a total transaction value of $135.7 billion, indicating a robust growth trend in the innovative drug sector [6]. - The innovative drug sector is expected to enter a profit realization phase by 2025, with several companies projected to turn losses into profits, driven by commercialized products and strategic collaborations [7]. Group 5: Future Outlook - The Chinese pharmaceutical industry has completed a transformation from generics to innovation, with companies like Hengrui Medicine and Hansoh Pharmaceutical emerging as leaders in the innovative drug space [8]. - The aging population and increasing demand for chronic disease treatments are expected to drive growth in the pharmaceutical sector, alongside advancements in technology such as AI in healthcare [8].

Group 1 - The Hang Seng Index rose by 0.54% at midday on February 10 [1] - The Hang Seng Tech Index increased by 0.84% [1] - CSPC Pharmaceutical Group saw a significant increase of 6% [1] - WuXi Biologics experienced a rise of 5.6% [1] - Innovent Biologics rose by 5.27% [1] - New Oriental Education & Technology Group declined by 4.71% [1] - Meituan saw a decrease of 3.02% [1]

港股频道更多独家策划、专家专栏，免费查阅>> 责任编辑：栎树 2月10日，信达生物(1801.HK)再度拉升涨超7%，现报92.5港元，总市值1568亿港元。消息上，信达生物日前与礼来制药达 成战略合作，推进肿瘤及免疫领域创新药全球研发。信达生物主导相关项目从药物发现至中国临床概念验证的研发工作， 礼来获大中华区外全球独家开发与商业化许可。信达生物将获88.5亿美元总付款，含3.5亿美元首付款及最高85亿美元里程 碑付款，还有权获大中华区外净销售额梯度销售分成。 摩根大通发表研究报告指出，信达生物与礼来达成战略合作，共同在全球范围开发聚焦于肿瘤和免疫学领域的新型生物制 剂。该行认为此次合作属正面惊喜，标志著信达生物迈向全球性生物制药公司历程中的又一个重要里程碑，并突显其研发 平台的实力。该行重申信达生物是其所覆盖的中国生物科技公司中的首选标的之一，予其"增持"评级，目标价为111港元。 ...

Group 1 - The core viewpoint of the article highlights the strategic collaboration between Innovent Biologics and Eli Lilly to jointly develop novel biologics focused on oncology and immunology globally [1] - The partnership is viewed as a positive surprise and marks a significant milestone in Innovent Biologics' journey towards becoming a global biopharmaceutical company, showcasing the strength of its R&D platform [1] - Innovent Biologics' management reiterated its long-term vision, primarily supported by a dual-engine growth strategy in the areas of generic biologics and oncology drugs [1] Group 2 - The report emphasizes the impressive execution capabilities of Innovent Biologics in its commercial and R&D product lines, as well as its strong business development abilities [1] - The firm maintains that Innovent Biologics is one of its top picks among Chinese biotech companies, reiterating an "overweight" rating with a target price of HKD 111 [1]